Education
About Us
Working with TipRanks
Follow Us
Lyell Immunopharma, Inc. (LYEL)
NASDAQ:LYEL
LYEL Stock Chart & Stats
$24.78
-$0.01(-1.66%)
At close: 4:00 PM EST
$24.78
-$0.01(-1.66%)
Day’s Range― - ―
52-Week Range$7.65 - $45.00
Previous CloseN/A
Volume124.06K
Average Volume (3M)105.21K
Market Cap
$526.32M
Enterprise Value$508.06M
Total Cash (Recent Filing)$247.22M
Total Debt (Recent Filing)$41.92M
Price to Earnings (P/E)―
Beta1.47
Next Earnings
May 12, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.86
Shares Outstanding21,243,954
10 Day Avg. Volume103,064
30 Day Avg. Volume105,213
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.12
Price to Sales (P/S)14614.51
P/FCF Ratio-3.49
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue14.11K
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-236.86
Forecast
1Y Price Target
$39.50Price Target Upside59.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-9.05
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Durability LeadershipAnalyst notes that Ronde-cel's meaningful durability in heavily treated lymphoma patients positions the therapy as a potential best-in-class option, which could drive stronger clinical uptake and pricing leverage.
Head-to-head Clinical DifferentiationAnalyst highlights that a randomized head-to-head trial versus approved CAR-T therapies could validate product differentiation and support premium positioning if results favor the company.
New Commercial Opportunity In Colorectal CancerAnalyst states that LYL273's encouraging activity in colorectal cancer that exceeds standard response levels creates a distinct second commercial opportunity beyond lymphoma, expanding revenue potential.
Bears Say
Adoption And Reimbursement RiskAnalyst warns that negative efficacy or safety findings could impede payer reimbursement and clinician adoption, undermining commercial rollout and revenue forecasts.
Efficacy UncertaintyAnalyst warns that reduced efficacy in broader or later-stage patient populations could weaken the therapies' value proposition and limit market adoption.
Unexpected Safety IssuesAnalyst cautions that an unexpected safety concern could alter the therapies' risk-benefit profile and lead to trial setbacks or tighter regulatory scrutiny.
Lyell Immunopharma News
LYEL FAQ
What was Lyell Immunopharma, Inc.’s price range in the past 12 months?
Lyell Immunopharma, Inc. lowest stock price was $7.65 and its highest was $45.00 in the past 12 months.
What is Lyell Immunopharma, Inc.’s market cap?
Lyell Immunopharma, Inc.’s market cap is $526.32M.
When is Lyell Immunopharma, Inc.’s upcoming earnings report date?
Lyell Immunopharma, Inc.’s upcoming earnings report date is May 12, 2026 which is in 60 days.
How were Lyell Immunopharma, Inc.’s earnings last quarter?
Lyell Immunopharma, Inc. released its earnings results on Mar 12, 2026. The company reported -$8.86 earnings per share for the quarter, missing the consensus estimate of -$2.232 by -$6.628.
Is Lyell Immunopharma, Inc. overvalued?
According to Wall Street analysts Lyell Immunopharma, Inc.’s price is currently Undervalued.
Does Lyell Immunopharma, Inc. pay dividends?
Lyell Immunopharma, Inc. does not currently pay dividends.
What is Lyell Immunopharma, Inc.’s EPS estimate?
Lyell Immunopharma, Inc.’s EPS estimate is -2.
How many shares outstanding does Lyell Immunopharma, Inc. have?
Lyell Immunopharma, Inc. has 21,243,954 shares outstanding.
What happened to Lyell Immunopharma, Inc.’s price movement after its last earnings report?
Lyell Immunopharma, Inc. reported an EPS of -$8.86 in its last earnings report, missing expectations of -$2.232. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Lyell Immunopharma, Inc.?
Currently, no hedge funds are holding shares in LYEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lyell Immunopharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$39.50 (59.40% Upside)
$39.50 (59.40% Upside)
Blogger Sentiment
Bullish
LYEL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 98.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $24.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 3.5%
Last 30 Days ▼ 14.4%
Last 30 Days ▼ 14.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
84.47%
12-Months-Change
Fundamentals
Return on Equity
-90.52%
Trailing 12-Months
Asset Growth
-34.12%
Trailing 12-Months
Company Description
Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
LYEL Stock 12 Month Forecast
Average Price Target
$39.50
▲(59.40% Upside)
Technical Analysis
Rocket Pharmaceuticals
―
Editas Medicine
―
Mereo Biopharma Group Plc
―
Replimune Group
―
―
Ownership Overview
30.78% Insiders
7.64% Mutual Funds
36.38% Other Institutional Investors
20.73% Public Companies and
Individual Investors